Rapid single B cell antibody discovery using nanopens and structured light.

ASC ELISA Monoclonal antibody NanOBlast OEP OptoElectro Positioning antibody discovery antibody generation nanofluidics structured light

Journal

mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829

Informations de publication

Date de publication:
Historique:
pubmed: 13 6 2019
medline: 31 1 2020
entrez: 13 6 2019
Statut: ppublish

Résumé

Accelerated development of monoclonal antibody (mAb) tool reagents is an essential requirement for the successful advancement of therapeutic antibodies in today's fast-paced and competitive drug development marketplace. Here, we describe a direct, flexible, and rapid nanofluidic optoelectronic single B lymphocyte antibody screening technique (NanOBlast) applied to the generation of anti-idiotypic reagent antibodies. Selectively enriched, antigen-experienced murine antibody secreting cells (ASCs) were harvested from spleen and lymph nodes. Subsequently, secreted mAbs from individually isolated, single ASCs were screened directly using a novel, integrated, high-content culture, and assay platform capable of manipulating living cells within microfluidic chip nanopens using structured light. Single-cell polymerase chain reaction-based molecular recovery on select anti-idiotypic ASCs followed by recombinant IgG expression and enzyme-linked immunosorbent assay (ELISA) characterization resulted in the recovery and identification of a diverse and high-affinity panel of anti-idiotypic reagent mAbs. Combinatorial ELISA screening identified both capture and detection mAbs, and enabled the development of a sensitive and highly specific ligand binding assay capable of quantifying free therapeutic IgG molecules directly from human patient serum, thereby facilitating important drug development decision-making. The ASC import, screening, and export discovery workflow on the chip was completed within 5 h, while the overall discovery workflow from immunization to recombinantly expressed IgG was completed in under 60 days.

Identifiants

pubmed: 31185801
doi: 10.1080/19420862.2019.1624126
pmc: PMC6748590
doi:

Substances chimiques

Antibodies, Monoclonal, Murine-Derived 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

1025-1035

Références

J Immunol Methods. 1999 Dec 10;231(1-2):11-23
pubmed: 10648924
J Pharm Biomed Anal. 1999 Apr;19(5):695-707
pubmed: 10698534
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Pharm Res. 2003 Nov;20(11):1885-900
pubmed: 14661937
Hybrid Hybridomics. 2003 Oct;22(5):329-31
pubmed: 14678651
Nature. 2005 Jul 21;436(7049):370-2
pubmed: 16034413
J Mol Biol. 2006 May 5;358(3):764-72
pubmed: 16563430
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17902-7
pubmed: 19004776
J Immunol Methods. 2009 Jan 30;340(2):164-9
pubmed: 19028499
Nature. 1991 Aug 15;352(6336):624-8
pubmed: 1907718
Lab Chip. 2009 Jun 21;9(12):1714-20
pubmed: 19495455
Nat Med. 2009 Sep;15(9):1088-92
pubmed: 19684583
J Immunol Methods. 2009 Oct 31;350(1-2):183-93
pubmed: 19716372
Lab Chip. 2010 Jan 21;10(2):165-72
pubmed: 20066243
Bioanalysis. 2010 Jun;2(6):1125-40
pubmed: 21083212
Nat Biotechnol. 2011 Mar;29(3):245-54
pubmed: 21390033
N Biotechnol. 2011 Sep;28(5):453-7
pubmed: 21473940
BMC Biotechnol. 2011 Apr 13;11:39
pubmed: 21486488
Nat Methods. 2011 May 22;8(7):581-6
pubmed: 21602799
Anal Chem. 2012 Feb 7;84(3):1267-73
pubmed: 22243404
Bioanalysis. 2012 Oct;4(20):2513-23
pubmed: 23157359
Nat Protoc. 2013 May;8(5):870-91
pubmed: 23558786
MAbs. 2014 Jan-Feb;6(1):143-59
pubmed: 24423622
Methods Mol Biol. 2014;1131:191-203
pubmed: 24515467
Anal Biochem. 2015 Feb 1;470:52-60
pubmed: 25447458
Anal Chem. 2015 Jan 20;87(2):997-1003
pubmed: 25479183
PLoS One. 2015 Jun 05;10(6):e0129125
pubmed: 26046845
AAPS J. 2015 Nov;17(6):1446-54
pubmed: 26265093
PLoS One. 2016 Mar 29;11(3):e0152282
pubmed: 27022949
Lab Chip. 2016 Apr 26;16(9):1636-43
pubmed: 27033300
Methods. 2017 Mar 1;116:34-42
pubmed: 27864085
BMC Biotechnol. 2017 Jan 9;17(1):3
pubmed: 28081707
F1000Res. 2017 Feb 7;6:113
pubmed: 28232867
Eur J Immunol. 2017 Aug;47(8):1389-1392
pubmed: 28608550
Mol Aspects Med. 2018 Feb;59:47-61
pubmed: 28927942
Hybridoma. 1989 Feb;8(1):107-15
pubmed: 2925206
MAbs. 2018 Feb/Mar;10(2):183-203
pubmed: 29300693
Adv Exp Med Biol. 2018;1068:89-102
pubmed: 29943298
Biotechnol Prog. 2018 Nov;34(6):1438-1446
pubmed: 30009534
Commun Biol. 2018 May 3;1:41
pubmed: 30271925
Eur J Immunol. 1996 Feb;26(2):444-8
pubmed: 8617316
Hybridoma. 1997 Aug;16(4):381-9
pubmed: 9309429

Auteurs

Aaron Winters (A)

a Department of Therapeutic Discovery, Amgen Research , Thousand Oaks , CA , USA.

Karyn McFadden (K)

a Department of Therapeutic Discovery, Amgen Research , Thousand Oaks , CA , USA.

John Bergen (J)

b Department of Therapeutic Discovery, Amgen Research , Burnaby , Canada.

Julius Landas (J)

b Department of Therapeutic Discovery, Amgen Research , Burnaby , Canada.
c Department of Pharmacokinetics & Drug Metabolism, University of British Columbia , Vancouver , Canada.

Kelly A Berry (KA)

b Department of Therapeutic Discovery, Amgen Research , Burnaby , Canada.

Anthony Gonzalez (A)

a Department of Therapeutic Discovery, Amgen Research , Thousand Oaks , CA , USA.

Hossein Salimi-Moosavi (H)

a Department of Therapeutic Discovery, Amgen Research , Thousand Oaks , CA , USA.
c Department of Pharmacokinetics & Drug Metabolism, University of British Columbia , Vancouver , Canada.

Christopher M Murawsky (CM)

b Department of Therapeutic Discovery, Amgen Research , Burnaby , Canada.

Philip Tagari (P)

a Department of Therapeutic Discovery, Amgen Research , Thousand Oaks , CA , USA.

Chadwick T King (CT)

b Department of Therapeutic Discovery, Amgen Research , Burnaby , Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH